Brodimoprim

This classification denotes a dihydrofolate reductase inhibitor with the molecular formula C13H15BrN4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V1YC7T6LLI, chemically known as 2,4-pyrimidinediamine, 5-((4-bromo-3,5-dimethoxyphenyl)methyl)- but more generally known as brodimoprim, which bears US NIH Compound Identifier 68760. European Medicines Agency schedules Brodimoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05898MIG. The term BRODIMOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, No. 5 1981, List 21). The World Health Organization schedules brodimoprim in its Anatomical Therapeutic Chemical (ATC) Classification. BRODIMOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: BRC1C(OC)CC(CC2C(NC(NC2)N)N)CC1OC.